Osilodrostat (Isturisa®). HTA ID: 22023

Assessment Status Rapid Review Complete
HTA ID 22023
Drug Osilodrostat
Brand Isturisa®
Indication For the treatment of endogenous Cushing’s syndrome in adults.
Assessment Process
Rapid review commissioned 21/04/2022
Rapid review completed 17/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osilodrostat compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.